Business

Skyepharma has reported that in-market sales of the flutiform fluticasone/formoterol MDI for the first 6 months of 2015 have totaled €65.1 million, up from €28.4 million in the first half of 2014, and the directors now predict that flutiform revenues will exceed previous expectations for the year. Skyepharma CEO Peter Grant commented, ""With a strong start to the … [Read more...] about Skyepharma reports revenues from flutiform have risen significantly

Raptor Pharmaceutical Co. plans to launch Quinsair inhaled levofloxacin inhalation solution in Europe and Canada by mid-2016, the company said after announcing that it has agreed to pay Tripex Pharmaceuticals $68.4 million upfront and up to $350 million in milestone payments and royalties to acquire global rights to the product. Quinsair (formerly Aeroquin) was … [Read more...] about Raptor Pharmaceutical acquires Quinsair levofloxacin inhalation solution

Novartis Healthcare Private Limited has announced the launch of the Sequadra indacaterol/glycopyrronium (110mcg/50mcg) DPI for the treatment of COPD in India. Novartis's indacaterol/glycopyrronium DPI is marketed in Europe and Japan as Ultibro Breezhaler. Novartis filed an NDA for the inhaler with the FDA in late 2014. Novartis India Country President Jawed Zia … [Read more...] about Novartis launches Sequadra indacaterol/glycopyrronium inhaler in India

Cipla has announced that it will launch the Synchrobreathe breath-actuated inhaler, which the company says requires low inspiratory flow to actuate, by the end of 2015. Company executives discussed the new inhaler at the 2015 South Africa Thoracic Society Conference. Cipla Global Head of Respiratory Frank Pieters commented, “Simple and intuitive, Synchrobreathe is … [Read more...] about Cipla announces the upcoming launch of the Synchrobreathe inhaler

Turing Pharmaceuticals, which is developing intranasal oxytocin for several indications has announced the completion of $90 million Series A financing round led by its Founder and CEO, Martin Shkreli. According to Turing, "the financing included participation from multiple preeminent institutional equity investors," but none were named. Retrophin divested intranasal … [Read more...] about Turing Pharmaceuticals announces that it has raised $90 million

Lupin Limited has officially opened its new Center of Excellence for Inhalation Research in Coral Springs, Florida with a ceremony officials from the city and the state of Florida. The new center will employ 45 OINDP specialists. Lupin CEO Vinita Gupta commented, "We are delighted to be making our mark in South Florida. With the talent and resources this state … [Read more...] about Lupin celebrates grand opening of Center of Excellence for Inhalation Research

According to a spokesperson for GlaxoSmithKline, GSK is aiming to hire a total of 100 employees in 2015 and another 30-40 employees in 2016 for a new DPI assembly line at its Zebulon, NC manufacturing facility. The Zebulon plant, which manufactures and packages 65 million Advair, Breo, Ventolin, Serevent, and Flovent inhalers per year, currently has 850 … [Read more...] about GSK hiring for new DPI production line at North Carolina facility

New Zealand-based Smartinhaler maker Adherium (formerly Nexus6) is looking to raise a minimum of A$20 million (~ US$14.7 million) up to a maximum of A$35 million (~US25.7 million) through an initial public offering on the Australian Securities Exchange (ASX). Between 40 and 70 million shares will be offered at 50 cents/share. Proceeds are intended for … [Read more...] about Adherium looks to raise at least A$20 million through IPO